NAMUR, BELGIUM--(Marketwired - Jun 3, 2014) - VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, announces the appointment of Dr. Habib Skaff to its Board of Directors, effective June 1, 2014. Dr. Skaff assumes the role of a non-executive director, providing independent expertise to the Board. Dr. Skaff will represent the interests of VolitionRx's shareholders alongside Dr. Martin (Dill) Faulkes (Executive Chairman), Cameron Reynolds (President and Chief Executive Officer) and non-executive directors Guy Innes and Dr. Alan Colman.
Dr. Skaff has served on VolitionRx's Scientific Advisory Board since 2011, and has a background in synthetic chemistry. Dr. Skaff received his PhD from the University of Massachusetts in 2004. He has co-authored 13 peer-reviewed scientific papers and is a co-inventor of 13 issued patents in the fields of chemistry, nanotechnology and biotechnology. Dr. Skaff co-founded Intezyne Technologies and currently serves as its Chief Executive Officer and Chairman of the Board.
Cameron Reynolds, CEO at VolitionRx, stated, "Dr. Skaff has been a member of our Scientific Advisory Board since 2011 and therefore brings a deep understanding of our business and technology to the Board. Coupled with his scientific achievements and experience in patenting and his knowledge of the US healthcare market, he will be a great asset to the Board. With our goal to up-list to a senior US stock exchange within the next 12 months, the appointment of Dr. Skaff brings us a step closer to fulfilling the corporate governance requirements of those exchanges."
Dr. Habib Skaff said, "After several years of serving on the Company's Scientific Advisory Board, I am pleased to join VolitionRx's corporate Board of Directors. I look forward to representing the interests of the company's shareholders as the company continues to increase awareness of its scientific developments amongst capital markets participants in the US."
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream -- an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.